Investigating satellite cell activation and hypertrophic signalling in skeletal muscle
Muscle growth research focuses on peptides that engage the IGF-1/mTOR axis and thymosin-mediated actin dynamics to promote skeletal muscle hypertrophy, satellite cell proliferation, and post-exercise recovery. IGF-1 LR3 is a long-acting analogue of Insulin-like Growth Factor 1 with reduced insulin-receptor binding affinity, making it a useful research tool for isolating anabolic signalling pathways. TB-500 is included in this category due to its role in satellite cell migration and muscle fibre repair.
IGF-1 LR3 activates the PI3K/Akt/mTOR pathway, driving protein synthesis and inhibiting muscle protein breakdown via FOXO3a suppression. Concurrently, it stimulates satellite cell proliferation via the MAPK/ERK cascade. TB-500 facilitates satellite cell homing to injury sites by upregulating actin polymerisation, enabling directed cell migration essential for myofibril repair.
| Протокол | Пептиды | Длительность | Дозировка | Конечная точка |
|---|---|---|---|---|
| Resistance Exercise Hypertrophy Model | IGF-1 LR3 | 28 days | 40–100 µg/kg · Once daily, 5 days/week | Muscle fibre cross-sectional area (CSA) via immunofluorescence, myosin heavy chain isoform expression, p70S6K phosphorylation (Western blot) |
| Satellite Cell Activation Study | IGF-1 LR3, TB-500 | 14 days | IGF-1 LR3: 50 µg/kg; TB-500: 2.5 mg per animal · Once daily | Satellite cell count (Pax7+/MyoD+ immunostaining), BrdU incorporation, myofibril fusion index |
Mechano Growth Factor (MGF), an IGF-1 splice variant expressed after mechanical loading, demonstrated potent satellite cell activation with hypertrophic effects superior to systemic IGF-1 in a rodent overload model.
PMID 14527957IGF-1 LR3 produced a 20–30% increase in lean body mass compared to equimolar native IGF-1, attributed to its reduced binding to IGFBPs and consequently prolonged receptor engagement.
PMID 10473097✓Плюсы
- IGF-1 LR3 half-life of ~20 hours vs ~10 minutes for native IGF-1 — practical for in vivo dosing without continuous infusion
- Directly engages mTOR pathway — one of the most studied anabolic signalling cascades
- Strong published evidence for satellite cell activation and lean mass increase in animal models
- TB-500 provides synergistic effect by improving vascular supply and satellite cell homing without direct anabolic stimulation
- Well-characterised mechanism enables precise experimental design
×Минусы
- IGF-1 LR3 must be reconstituted in dilute acetic acid, not water — incorrect reconstitution causes tissue damage at injection site
- Supraphysiological IGF-1 levels carry theoretical oncogenic risk due to broad receptor activity
- Hypoglycaemia risk at higher doses — blood glucose monitoring recommended in diabetic-prone models
- IGF-1 LR3 is essentially unavailable from EU vendors as of 2026 — contact vendors directly
- No human clinical data; animal study results may not translate
- Most expensive category of EU research peptides
Why use IGF-1 LR3 instead of native IGF-1?
IGF-1 LR3 has an arginine substitution at position 3 that dramatically reduces its affinity for IGF-binding proteins (IGFBPs). This extends its half-life from ~10 minutes to ~20 hours, making it far more practical for in vivo dosing studies without continuous infusion.
What is the role of TB-500 in muscle growth research?
TB-500 does not directly stimulate protein synthesis, but it facilitates satellite cell migration to sites of muscle damage and promotes angiogenesis, thereby improving the microenvironmental conditions for muscle repair and hypertrophic remodelling.
Больше из этого региона.
Другие статьи о поставщиках, регуляторной базе и исследовательских пептидах этого региона.
- 2026-10-08Earlier versions gave IGF-1 LR3 as S2.4 and CJC-1295 and ipamorelin as S2.5. On the 2026 WADA Prohibited List they are in S2.3 (growth factors) and S2.2.4 (growth hormone releasing factors).